Quantbot Technologies LP increased its position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 6.2% during the first quarter, according to its most recent filing with the SEC. The fund owned 1,650 shares of the medical equipment provider’s stock after buying an additional 96 shares during the period. Quantbot Technologies LP’s holdings in Zimmer Biomet Holdings were worth $201,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently bought and sold shares of ZBH. Aberdeen Asset Management PLC UK boosted its position in Zimmer Biomet Holdings by 12.3% in the first quarter. Aberdeen Asset Management PLC UK now owns 44,510 shares of the medical equipment provider’s stock worth $5,435,000 after buying an additional 4,889 shares during the last quarter. Delta Lloyd NV bought a new position in Zimmer Biomet Holdings during the first quarter worth approximately $12,278,000. Nordea Investment Management AB boosted its position in Zimmer Biomet Holdings by 25.0% in the first quarter. Nordea Investment Management AB now owns 4,931,281 shares of the medical equipment provider’s stock worth $602,159,000 after buying an additional 987,398 shares during the last quarter. Pacer Advisors Inc. boosted its position in Zimmer Biomet Holdings by 3.2% in the first quarter. Pacer Advisors Inc. now owns 4,247 shares of the medical equipment provider’s stock worth $519,000 after buying an additional 132 shares during the last quarter. Finally, Envestnet Asset Management Inc. boosted its position in Zimmer Biomet Holdings by 22.1% in the first quarter. Envestnet Asset Management Inc. now owns 41,437 shares of the medical equipment provider’s stock worth $5,059,000 after buying an additional 7,492 shares during the last quarter. Hedge funds and other institutional investors own 84.63% of the company’s stock.

Institutional Ownership by Quarter for Zimmer Biomet Holdings (NYSE:ZBH)

Shares of Zimmer Biomet Holdings, Inc. (NYSE ZBH) opened at 125.92 on Friday. The stock’s 50 day moving average is $120.97 and its 200-day moving average is $116.09. The firm has a market cap of $25.39 billion, a PE ratio of 51.54 and a beta of 1.23. Zimmer Biomet Holdings, Inc. has a 52 week low of $95.63 and a 52 week high of $133.21.

Zimmer Biomet Holdings (NYSE:ZBH) last released its quarterly earnings results on Thursday, April 27th. The medical equipment provider reported $2.13 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $2.11 by $0.02. Zimmer Biomet Holdings had a return on equity of 16.80% and a net margin of 6.36%. The business had revenue of $1.98 billion during the quarter, compared to analysts’ expectations of $1.96 billion. During the same quarter in the prior year, the business earned $2.00 earnings per share. The company’s quarterly revenue was up 3.8% compared to the same quarter last year. On average, equities analysts predict that Zimmer Biomet Holdings, Inc. will post $8.54 EPS for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, July 28th. Investors of record on Friday, June 23rd will be issued a dividend of $0.24 per share. This represents a $0.96 dividend on an annualized basis and a yield of 0.76%. The ex-dividend date is Wednesday, June 21st. Zimmer Biomet Holdings’s dividend payout ratio is presently 39.67%.

WARNING: “Zimmer Biomet Holdings, Inc. (ZBH) Shares Bought by Quantbot Technologies LP” was first reported by Financial Market News and is the property of of Financial Market News. If you are accessing this piece on another site, it was stolen and reposted in violation of U.S. and international copyright and trademark law. The original version of this piece can be read at https://www.financial-market-news.com/2017/06/17/zimmer-biomet-holdings-inc-zbh-shares-bought-by-quantbot-technologies-lp.html.

A number of research analysts have recently commented on the stock. Citigroup Inc. upped their price target on shares of Zimmer Biomet Holdings from $108.00 to $130.00 and gave the stock a “neutral” rating in a report on Friday, June 9th. ValuEngine cut shares of Zimmer Biomet Holdings from a “buy” rating to a “hold” rating in a report on Friday, June 2nd. Goldman Sachs Group, Inc. (The) initiated coverage on shares of Zimmer Biomet Holdings in a report on Tuesday, May 16th. They set a “sell” rating and a $92.00 target price on the stock. Canaccord Genuity reiterated a “buy” rating on shares of Zimmer Biomet Holdings in a report on Friday, April 28th. Finally, Oppenheimer Holdings, Inc. set a $132.00 target price on shares of Zimmer Biomet Holdings and gave the stock a “buy” rating in a report on Friday, April 28th. Two analysts have rated the stock with a sell rating, four have given a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the company’s stock. Zimmer Biomet Holdings has a consensus rating of “Buy” and an average price target of $135.88.

In related news, insider David C. Dvorak sold 87,331 shares of the company’s stock in a transaction on Thursday, April 27th. The stock was sold at an average price of $116.47, for a total transaction of $10,171,441.57. Following the transaction, the insider now owns 381,886 shares of the company’s stock, valued at $44,478,262.42. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Chad F. Phipps sold 6,200 shares of the company’s stock in a transaction on Friday, May 5th. The stock was sold at an average price of $116.76, for a total value of $723,912.00. The disclosure for this sale can be found here. Insiders have sold 112,302 shares of company stock worth $13,230,422 in the last ninety days. 1.07% of the stock is currently owned by corporate insiders.

About Zimmer Biomet Holdings

Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.

Want to see what other hedge funds are holding ZBH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zimmer Biomet Holdings, Inc. (NYSE:ZBH).

Receive News & Ratings for Zimmer Biomet Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.